Key takeaways
- A new Nature study shows that replacing BMI with a 'clinical obesity' framework would reverse obesity diagnoses for millions of US patients.
What happened
In November 2026, a landmark study published in the journal Nature evaluated a diagnostic framework proposed by a Lancet commission to replace body mass index (BMI) with a new "clinical obesity" classification system. The study revealed that replacing traditional BMI with this health-focused diagnostic framework would completely flip obesity diagnoses for millions of patients, redefining who is classified as having the disease based on actual health complications rather than simple height-and-weight math.
Why it matters
For millions of Americans seeking medical weight-loss treatments, this proposal could fundamentally reshape eligibility for GLP-1 insurance coverage and online telehealth prescriptions. Currently, commercial insurance companies and telehealth platforms rely almost exclusively on strict BMI cutoffs—typically a BMI of 30 or greater, or 27 with a weight-related comorbidity—to approve coverage for brand-name medications like Wegovy and Zepbound.
By shifting the diagnostic criteria from a blunt weight-to-height ratio to "clinical obesity" (which evaluates how weight actively harms a person's cardiovascular, metabolic, or physical health), many patients with a high BMI but no current metabolic complications could lose their official diagnosis. Conversely, millions of individuals who do not meet standard BMI cutoffs but suffer from visceral fat storage and metabolic damage could finally secure a formal obesity diagnosis. This shift could open the door to insurance coverage for patients who are currently forced to pay entirely out-of-pocket.
What the data says
The Nature study analyzed the real-world impact of the diagnostic framework proposed by the Lancet commission. The commission's model bifurcates the disease into two distinct phases:
- Preclinical Obesity: Individuals who carry excess weight but do not currently exhibit weight-related health complications.
- Clinical Obesity: Individuals whose weight is actively damaging their health, leading to metabolic, cardiovascular, joint, or other physical complications, and who face a higher risk of dire health outcomes.
According to the study, replacing the entrenched BMI standard with this clinical framework would instantly reverse diagnoses for millions of people. Some patients currently labeled as having obesity would be reclassified as healthy or preclinical, while others with lower BMIs who carry dangerous abdominal fat would be newly classified as having clinical obesity.
Currently, BMI remains deeply entrenched across the US healthcare system, dictating FDA drug approvals, commercial insurance coverage criteria, and state Medicaid policies. However, the metric has faced mounting criticism for failing to account for differences in body composition, muscle mass, and variation in where fat is stored.
How it compares
Under current FDA guidelines and telehealth screening protocols, accessing GLP-1 medications relies on rigid numbers. For example, to qualify for a semaglutide or tirzepatide prescription, you must typically meet these criteria:
- A BMI of 30 kg/m² or higher.
- A BMI of 27 kg/m² or higher with at least one weight-related condition, such as high blood pressure or type 2 diabetes.
If clinical obesity becomes the primary diagnostic standard, this binary screening math will change. Patients would be evaluated using comprehensive metabolic panels, cardiovascular assessments, and physical health markers rather than just an office scale.
For cash-pay buyers utilizing telehealth providers to access compounded vs brand-name semaglutide, this shift could alter online medical intake forms. Instead of simply entering height and weight to clear a digital threshold, patients may need to submit recent lab work or blood pressure readings to prove clinical necessity.
In terms of cost, getting a clinical obesity diagnosis under the new system could save patients thousands of dollars. Brand-name GLP-1s like Wegovy and Zepbound carry retail list prices exceeding $1,000 per month. Securing insurance coverage via a clinical obesity diagnosis reduces this to a standard copay (often $25 to $50), whereas failing to meet the new criteria could force patients to seek the cheapest telehealth GLP-1 cash-pay options, which typically range from $200 to $400 monthly for compounded alternatives.
How this fits the bigger picture
This Nature study is part of a broader clinical movement to align medical diagnoses with actual health outcomes rather than arbitrary numeric cutoffs. We have already seen how rigid BMI rules create severe disparities in the US healthcare system; for instance, as explored in our coverage of how FDA GLP-1 rules conflict with Asian obesity standards, standard BMI cutoffs systematically deny insurance coverage to Asian Americans who experience severe metabolic complications at much lower body weights. A shift toward a "clinical obesity" definition would directly address this screening gap, allowing clinical health markers to dictate care rather than a flawed mathematical formula.
Furthermore, medical research is increasingly proving that GLP-1 drugs do far more than lower weight—they directly treat the clinical complications that the Lancet commission prioritizes. Recent clinical trials have demonstrated that these therapies address severe comorbidities, such as how Lilly’s retatrutide cuts knee arthritis pain or how other GLP-1 formulations treat cardiovascular disease and sleep apnea. Shifting the diagnostic standard to "clinical obesity" acknowledges that these medications are critical metabolic therapies rather than cosmetic weight-loss treatments, which may eventually force insurance companies to reform what insurance covers for GLP-1s.
What happens next
The proposal by the Lancet commission and the subsequent validation in the Nature study are significant milestones, but change will not happen overnight. The transition away from BMI faces major hurdles, as insurance billing codes, FDA drug labeling, and electronic health record systems are all built around the traditional metric.
Over the next few years, medical societies and obesity advocacy groups are expected to lobby the World Health Organization (WHO) and the American Medical Association (AMA) to formally adopt the clinical obesity framework. Meanwhile, telehealth platforms and commercial insurers will continue to use standard BMI cutoffs until official FDA prescribing labels are updated to reflect health-based diagnostic criteria rather than body mass index.
Disclaimer: CompareRx does not provide medical advice. Always consult a licensed healthcare provider to determine the best treatment plan for your specific health needs.

